# US 8,278,103 B2 · Oligonucleotides comprising alternating segments and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,103 B2
- Document ID: US8278103B2
- Status: Granted
- Kind: B2
- Application number: 10/503,120
- Filed: 2003-01-31
- Published: 2005-06-30
- Granted: 2012-10-02
- Earliest claimed: 2002-02-01
- Assignees: McGill University
- Inventors: Masad J. Damha; Michael A. Parniak
- Web page: https://patentgrep.com/patent/US8278103B2

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/32: of the sugar
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/323: modified ring structure
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to oligonucleosides having alternating segments of sugar-modified nucleosides and 2′-deoxynucleosides, and uses thereof. The invention further relates to oligonucleotides having alternating segments of sugar-modified nucleotides and 2′-deoxynucleotides, and uses thereof. Such uses include the preparation of antisense oligonucleotides and their use for the prevention or depletion of function of a target nucleic acid of interest, such as an RNA, in a system. Accordingly, an oligonucleotide of the invention is useful for therapeutic, analytical and diagnostic methods and uses, as well as a component of compositions and commercial packages corresponding to such methods and uses.

## Claims

### Claim 1

An oligonucleotide comprising alternating first and second segments, wherein:
said first segment consists of all arabinonucleotides and comprises at least one arabinonucleotide
said second segment consists of all 2′-deoxyribonucleotides and comprises at least one 2′-deoxyribonucleotide
said oligonucleotide comprises at least 2 of each of said first and second segments thereby comprising at least 4 alternating segments wherein the number of residues within each first segments and each second segments may be the same or variable from one segment to another,
at least one first segment comprises at least two arabinonucleotides and at least one second segment comprises at least two 2′-deoxyribonucleotides, and
all internucleotide linkages of the oligonucleotide consist of phosphorothioate linkages.

### Claim 2 (depends on 1)

The oligonucleotide of claim 1, wherein said oligonucleotide is capable of adopting a DNA-like conformation.

### Claim 3 (depends on 1)

The oligonucleotide of claim 1, wherein all arabinonucleoides have flourine as A 2′ substitute.

### Claim 4 (depends on 1)

The oligonucleotide of claim 1, wherein said segments each independently comprise about 2 to about 5 arabinonucleotide or 2′-deoxyribonucleotides.

### Claim 5 (depends on 4)

The oligonucleotide of claim 4, wherein said segments each independently comprise about 3 to about 4 arabinonucleotide or 2′-deoxyribonucleotides.

### Claim 6 (depends on 5)

The oligonucleotide of claim 5, wherein said segments each independently comprise about 3 arabinonucleotide or 2′-deoxyribonucleotides.

### Claim 7 (depends on 1)

The oligonucleotide of claim 1, wherein said oligonucleotide has a structure selected from the group consisting of:
a)
(Ax-Dy)n
I
b)
(Dy-Ax)n
II
c)
(Ax-Dy)m-Ax-Dy-Ax
III
d)
(Dy-Ax)m-Dy-Ax-Dy
IV
wherein each of m, x and y are each independently an integer greater than or equal to 1, n is an integer greater than or equal to 2, A is an arabinonucleotide and D is a 2′-deoxyribonucleotide, wherein at least one instance of each of x and y is greater than or equal to 2.

### Claim 8 (depends on 1)

The oligonucleotide of claim 1, wherein said arabinonucleotide comprises a 2′ substituent selected from the group consisting of fluorine, hydroxyl, amino, cyano, azido, —CH═CH2, —C≡CH, alkyl, functionalized alkyl, alkoxy and functionalized alkoxy groups.

### Claim 9 (depends on 8)

The oligonucleotide of claim 8, wherein said alkyl group is a lower alkyl group.

### Claim 10 (depends on 9)

The oligonucleotide of claim 9, wherein said lower alkyl group is selected from the group consisting of methyl, ethyl and propyl groups.

### Claim 11 (depends on 8)

The oligonucleotide of claim 8, wherein said functionalized alkyl group is selected from the group consisting of methylamino , ethylamino and propylamino groups.

### Claim 12 (depends on 8)

The oligonucleotide of claim 8, wherein said alkoxy group is selected from the group consisting of methoxy, ethoxy and propoxy groups.

### Claim 13 (depends on 8)

The oligonucleotide of claim 8, wherein said functionalized alkoxy group is —O(CH2)q—R, wherein q=2, 3 or 4 and —R is selected from the group consisting of —NH2, —OCH3, and —OCH2CH3 groups.

### Claim 14 (depends on 7)

The oligonucleotide of claim 7 , wherein the arabinonucleotide is a 2′fluoroarabinonucleotide (2′F-ANA).

### Claim 15 (depends on 1)

The oligonucleotide of claim 1, wherein said oligonucleotide consists of about 30 or fewer nucleotides.

### Claim 16 (depends on 15)

The oligonucleotide of claim 15, wherein said oligonucleotide consists of about 8 to about 25 nucleotides.

### Claim 17 (depends on 16)

The oligonucleotide of claim 16, wherein said oligonucleotide consists of about 18 nucleotides.

### Claim 18 (depends on 7)

The oligonucleotide of claim 7, wherein said oligonucleotide has structure I wherein x=3, y=3 and n=3, thereby having a structure:
A-A-A-D-D-D-A-A-A-D-D-D-A-A-A-D-D-D.

### Claim 19 (depends on 1)

The oligonucleotide of claim 1, wherein said oligonucleotide is antisense to a target RNA.

### Claim 20 (depends on 19)

A composition comprising the oligonucleotide according to claim 19 in admixture with a pharmaceutically acceptable carrier.

### Claim 21 (depends on 19)

A commercial package comprising the oligonucleotide according to claim 19 together with instructions for its use.

### Claim 22 (depends on 21)

The commercial package of claim 21, wherein said instructions are for a use selected from the group consisting of:
a. inducing RNase H-mediated cleavage of a target RNA in a system;
b. preventing or decreasing translation of a target RNA in a system;
c. preventing or decreasing reverse transcription of a target RNA in a system;
d. preventing or decreasing replication of a target RNA in a system;
e. detecting the presence of a target RNA in a system;
f. validating a gene target in a system;
g. preventing or treating a disease related to a target RNA in a system; and
h. any combination of a. to g.

### Claim 23 (depends on 7)

The oligonucleotide of claim 7, wherein the arabinonucleotide has fluorine as a 2′ substituent, and the oligonucleotide has structure (Ax-Dy)n.
